In contract, the adoption of ddPCR for detecting common melanoma mutations including BRAF, NRAS, KIT, and TERT significantly improved sensitivity, allowing ctDNA to be distinguished from total cfDNA in approximately 80% of melanoma patients [72]. The gene discussed is NRAS; the disease is melanoma.